ArticleFrontiers in microbiology2022
Immunogenicity of Mycobacterial Extracellular Vesicles Isolated From Host-Related Conditions Informs About Tuberculosis Disease Status.
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Cell Envelope Remodeling and Lipid Metabolism Coordinate Extracellular Vesicle Output in Mycobacterium Tuberculosis.Journal of extracellular biology · 2026Article
- Extracellular Vesicles of Mycobacterium tuberculosis Serve as a Virulence Factor - Current Research Applications.Current microbiology · 2026Review
- Single-Cell Immune Atlases to Map Small Extracellular Vesicle Cargo in Tuberculosis-Diabetes Comorbidity: A Narrative Review and Conceptual Roadmap.International journal of molecular sciences · 2026Review
- Article
- Establishment of minimum protein standards forMycobacteria (London, England) · 2025Article
- The value of LAM and LprG in extracellular vesicles in the diagnostic and therapeutic field of renal tuberculosis.Frontiers in tuberculosis · 2025Review
- From Proteomics to Diagnosis: Biomarker Discovery in Tuberculosis Research.Current medicinal chemistry · 2025Review
- The role of antibiotic-derived mycobacterial vesicles in tuberculosis pathogenesis.Scientific reports · 2024Article
- Live Attenuated Vaccines against Tuberculosis: Targeting the Disruption of Genes Encoding the Secretory Proteins of Mycobacteria.Vaccines · 2024Review
- Review
- Extracellular Vesicles in Pathophysiology: A Prudent Target That Requires Careful Consideration.Cells · 2024Review
- Spotlight on mycobacterial lipid exploitation using nanotechnology for diagnosis, vaccines, and treatments.Nanomedicine : nanotechnology, biology, and medicine · 2023Review
- An update on our understanding of Gram-positive bacterial membrane vesicles: discovery, functions, and applications.Frontiers in cellular and infection microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) still represents a major global health problem affecting over 10 million people worldwide. The gold-standard procedures for TB diagnosis are culture and nucleic acid amplification techniques. In this context, both lipoarabinomannan (LAM) urine test and rapid molecular tests have been major game changers. However, the low sensitivity of the former and the cost and the prohibitive infrastructure requirements to scale-up in endemic regions of the latter, make the improvement of the TB diagnostic landscape a priority. Most forms of life produce extracellular vesicles (EVs), including bacteria despite differences in bacterial cell envelope architecture. We demonstrated that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.